Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:C10AX14
|
| gptkbp:CASNumber |
gptkb:1245916-14-6
|
| gptkbp:developedBy |
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals |
| gptkbp:form |
pre-filled pen
150 mg 75 mg pre-filled syringe |
| gptkbp:genericName |
gptkb:alirocumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Praluent
|
| gptkbp:indication |
gptkb:familial_hypercholesterolemia
cardiovascular disease risk reduction |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:monoclonal_antibody
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
PCSK9 inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:reduces |
gptkb:LDL_cholesterol
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
injection site reaction
nasopharyngitis flu-like symptoms |
| gptkbp:target |
gptkb:PCSK9_protein
|
| gptkbp:bfsParent |
gptkb:Sanofi
|
| gptkbp:bfsLayer |
5
|